Literature DB >> 22207252

Lessons learned from phagocytic function studies in a large cohort of patients with recurrent infections.

Baruch Wolach1, Ronit Gavrieli, Dirk Roos, Sivan Berger-Achituv.   

Abstract

BACKGROUND: There is a paucity of data on the relationship between demographic characteristics, specific clinical manifestations, and neutrophil dysfunction, guiding physicians to decide which clinical signs and symptoms are a code for an underlying phagocytic disorder.
METHODS: The data over a 21-year period of all adult and pediatric patients referred to our Laboratory for Leukocyte Functions with recurrent pyogenic infections were analyzed. Neutrophil function studies included chemotaxis, superoxide production (SOP), bactericidal activity (BA), and specific studies in case of suspected primary phagocytic disorder (PPD).
RESULTS: Neutrophil dysfunction was found in 33.6% of 998 patients; chemotaxis in 16.6%, SOP in 6%, and BA in 24.5%. The younger the patient and the more organ systems involved, the greater the probability of finding phagocytic impairment. Impaired chemotaxis correlated with recurrent aphthous stomatitis, infections associated with elevated IgE, and purulent upper respiratory tract infections. Impaired SOP and BA correlated with deep-seated abscesses, recurrent lymphadenitis, sepsis, and bone and joint and central nervous system infections. PPDs were identified in 5.7%, chronic granulomatous disease in 4.8%, neutrophil glucose-6-phosphate dehydrogenase deficiency in 0.3%, leukocyte adhesion deficiency type 1 in 0.4%, and myeloperoxidase deficiency in 0.2%. Phagocytic evaluation contributed to the diagnosis of hyperimmunoglobulin-E syndrome (n = 21) and Chediak-Higashi syndrome (n = 3).
CONCLUSIONS: PPDs are identified in 5.7% of patients with recurrent pyogenic infections; in the remainder, phagocytic dysfunction may be related to deleterious effects of persistent infection, drug consumption, or disorders not yet established.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22207252     DOI: 10.1007/s10875-011-9633-4

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  52 in total

1.  The incidence of primary immunodeficiency syndromes in Israel.

Authors:  Hana Golan; Ilan Dalal; Ben-Zion Garty; Menachem Schlesinger; Jacob Levy; Zeev Handzel; Baruch Wolach; Menachem Rottem; Arnon Goldberg; Rami Tamir; Ariel Koren; Yael Levy; Yitzhak Katz; Justine Passwell; Amos Etzioni
Journal:  Isr Med Assoc J       Date:  2002-11       Impact factor: 0.892

2.  Neonatal neutrophil inflammatory responses: parallel studies of light scattering, cell polarization, chemotaxis, superoxide release, and bactericidal activity.

Authors:  B Wolach; D Sonnenschein; R Gavrieli; O Chomsky; A Pomeranz; I Yuli
Journal:  Am J Hematol       Date:  1998-05       Impact factor: 10.047

Review 3.  [Job syndrome (hyper-IgE) and hypo-IgA. A rare association of immunodeficiencies].

Authors:  A Mazzone; S Girola; G Fossati; I Mazzucchelli; G Ricevuti
Journal:  Recenti Prog Med       Date:  1996-02

4.  Functional differentiation of normal human neutrophils.

Authors:  L Glasser; R L Fiederlein
Journal:  Blood       Date:  1987-03       Impact factor: 22.113

5.  Chemotaxis of polymorphonuclear neutrophils (PMN) in patients suffering from recurrent infection.

Authors:  H Brenneis; A Schmidt; P Blaas-Mautner; I Wörner; R Ludwig; G M Hänsch
Journal:  Eur J Clin Invest       Date:  1993-11       Impact factor: 4.686

Review 6.  Leukocyte adhesion deficiencies: molecular basis, clinical findings, and therapeutic options.

Authors:  Amos Etzioni
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

7.  Diurnal fluctuation of leukocyte G6PD activity. A possible explanation for the normal neutrophil bactericidal activity and the low incidence of pyogenic infections in patients with severe G6PD deficiency in Israel.

Authors:  Baruch Wolach; Meir Ashkenazi; Rami Grossmann; Ronit Gavrieli; Ziva Friedman; Nava Bashan; Dirk Roos
Journal:  Pediatr Res       Date:  2004-02-18       Impact factor: 3.756

8.  Use of recombinant human interferon gamma to enhance neutrophil chemotactic responses in Job syndrome of hyperimmunoglobulinemia E and recurrent infections.

Authors:  J D Jeppson; H S Jaffe; H R Hill
Journal:  J Pediatr       Date:  1991-03       Impact factor: 4.406

9.  Influence of gender and oral contraceptives intake on innate and inflammatory response. Role of neuroendocrine factors.

Authors:  E Giraldo; M D Hinchado; J J Garcia; Eduardo Ortega
Journal:  Mol Cell Biochem       Date:  2008-04-10       Impact factor: 3.396

Review 10.  Educational paper: Defects in number and function of neutrophilic granulocytes causing primary immunodeficiency.

Authors:  J Merlijn van den Berg; Taco W Kuijpers
Journal:  Eur J Pediatr       Date:  2011-10-04       Impact factor: 3.183

View more
  10 in total

1.  Variable clinical expressivity of STAT3 mutation in hyperimmunoglobulin E syndrome: genetic and clinical studies of six patients.

Authors:  Ofir Wolach; Taco Kuijpers; Josef Ben-Ari; Ronit Gavrieli; Neta Feinstein-Goren; Marielle Alders; Ben Zion Garty; Baruch Wolach
Journal:  J Clin Immunol       Date:  2014-01-23       Impact factor: 8.317

2.  Myeloperoxidase Attenuates Pathogen Clearance during Plasmodium yoelii Nonlethal Infection.

Authors:  Wiebke Theeß; Julie Sellau; Christiane Steeg; Anna Klinke; Stephan Baldus; Jakob P Cramer; Thomas Jacobs
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

3.  Evidence for bistable bacteria-neutrophil interaction and its clinical implications.

Authors:  Roy Malka; Baruch Wolach; Ronit Gavrieli; Eliezer Shochat; Vered Rom-Kedar
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

4.  Analysis of Chronic Granulomatous Disease in the Kavkazi Population in Israel Reveals Phenotypic Heterogeneity in Patients with the Same NCF1 mutation (c.579G>A).

Authors:  Baruch Wolach; Ronit Gavrieli; Martin de Boer; Karin van Leeuwen; Ofir Wolach; Galia Grisaru-Soen; Arnon Broides; Amos Etzioni; Raz Somech; Dirk Roos
Journal:  J Clin Immunol       Date:  2018-02-06       Impact factor: 8.317

Review 5.  Staphylococcus aureus - antimicrobial resistance and the immunocompromised child.

Authors:  J Chase McNeil
Journal:  Infect Drug Resist       Date:  2014-05-07       Impact factor: 4.003

6.  Effect of silica and gold nanoparticles on macrophage proliferation, activation markers, cytokine production, and phagocytosis in vitro.

Authors:  Simona Bancos; David L Stevens; Katherine M Tyner
Journal:  Int J Nanomedicine       Date:  2014-12-24

7.  Eosinophilia and reduced STAT3 signaling affect neutrophil cell death in autosomal-dominant Hyper-IgE syndrome.

Authors:  Susan Farmand; Bernhard Kremer; Monika Häffner; Katrin Pütsep; Peter Bergman; Mikael Sundin; Henrike Ritterbusch; Maximilian Seidl; Marie Follo; Philipp Henneke; Birgitta Henriques-Normark
Journal:  Eur J Immunol       Date:  2018-10-29       Impact factor: 5.532

Review 8.  Etiopathogenesis of recurrent aphthous stomatitis and the role of immunologic aspects: literature review.

Authors:  Zuzanna Slebioda; Elżbieta Szponar; Anna Kowalska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-11-12       Impact factor: 4.291

9.  In vitro model of production of antibodies; a new approach to reveal the presence of key bacteria in polymicrobial environments.

Authors:  Chongcong Wu; Sravya Nakka; Sepahdar Mansouri; Torbjörn Bengtsson; Tayeb Nayeri; Fariba Nayeri
Journal:  BMC Microbiol       Date:  2016-09-09       Impact factor: 3.605

10.  Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection.

Authors:  Aisling F Brown; Alison G Murphy; Stephen J Lalor; John M Leech; Kate M O'Keeffe; Micheál Mac Aogáin; Dara P O'Halloran; Keenan A Lacey; Mehri Tavakol; Claire H Hearnden; Deirdre Fitzgerald-Hughes; Hilary Humphreys; Jérôme P Fennell; Willem J van Wamel; Timothy J Foster; Joan A Geoghegan; Ed C Lavelle; Thomas R Rogers; Rachel M McLoughlin
Journal:  PLoS Pathog       Date:  2015-11-05       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.